Advanced BioScience Laboratories, Inc.

16 articles about Advanced BioScience Laboratories, Inc.

• ABL Awarded $Multimillion Contract to Provide Manufacturing and Nonclinical Services to Support Development of Promising Therapeutics for the NINDS

  11/4/2022

  Advanced BioScience Laboratories announced it is one of three contractors awarded an Indefinite Delivery, Indefinite Quantity contract for "Manufacturing and Nonclinical Studies support for Development of Therapeutic Biotechnology Products for Neurological-related Disorders" by the NINDS of the NIH of the HHS.

• ABL Awarded NIH Contract for Continued Support of HIV Vaccine Development

  10/20/2022

  Advanced BioScience Laboratories announced it has been awarded a contract for "Preclinical and translational vaccine development for HIV and other candidate agents" by the Division of AIDS within the National Institute of Allergy and Infectious Disease of the National Institutes of Health.

• ABL Europe, University Clinic of Tuebingen and Prime Vector Technologies partner for a 2nd generation COVID-19 vaccine

  11/5/2020

  ABL Europe uses viral vector expertise to collaborate with University Clinic of Tuebingen and Prime Vector Technologies for development and manufacture of its 2nd generation SARS-CoV-2 Vaccine Candidate

• Expression Therapeutics Selects Advanced BioScience Laboratories, Inc. To Support Cell Line Development For Hemophilia A Factor VIII Infusion Therapy

  8/18/2014

• Advanced BioScience Laboratories, Inc. Selected by PATH to Manufacture Novel Shigella Vaccine Candidate

  10/1/2013

• Advanced BioScience Laboratories, Inc. Awards Avid Bioservices, Inc. HIV Vaccine Development and Manufacturing Contract

  9/27/2012

• Advanced BioScience Laboratories, Inc. Awarded National Institutes of Health (NIH) Contract to Fund Up to $102 Million in Biologics Manufacturing and Characterization Services

  8/1/2012

• Advanced BioScience Laboratories, Inc. to Provide Cell Line Development, Process Development, and cGMP Manufacturing Services of scuPA for the University of Texas Health Science Center at Tyler

  6/13/2012

• InViragen Enlists Advanced BioScience Laboratories, Inc. for Manufacture of Master Virus Seed Stock for Plague Vaccine Development

  2/8/2012

• Trophogen, Inc. Selects Advanced BioScience Laboratories, Inc. as Contract Manufacturer for Recombinant, Human Follicle-Stimulating Hormone (rhFSH) Analog

  1/9/2012

• Advanced BioScience Laboratories, Inc. Launches New Website

  11/14/2011

• Advanced BioScience Laboratories, Inc. Awarded “NIAID Preclinical Development Support” Contract with National Institutes of Health-Maximum Funding Potential of $102,500,000 Over Seven Years

  9/15/2011

• Advanced BioScience Laboratories, Inc. to Manufacture Hawaii Biotech, Inc.'s Dengue Vaccine for Clinical Trial

  5/25/2010

• Inovio Biomedical Corporation Licenses Electroporation Delivery Technology to Leading U.S. Government Contractor, Advanced BioScience Laboratories, Inc.

  5/27/2008

• New Hope For HIV Vaccine: Unique HIV Vaccine Formula, Developed By Advanced BioScience Laboratories, Inc. and The University of Massachusetts - Amherst, Elicits Strong Immune Responses, Findings Confirmed By University of Alabama at Birmingham Study

  5/23/2008

• Althea Technologies, Inc. Awarded Advanced BioScience Laboratories, Inc. Contract To Produce DNA-Based HIV Vaccine For U.S. National Institute of Allergy, Infectious Disease

  8/29/2006